drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00344 | DB01364 | 1,302 | 22 | [
"DDInter1543",
"DDInter650"
] | Protriptyline | Ephedrine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Major | 2 | [
[
[
1302,
25,
22
]
],
[
[
1302,
6,
7390
],
[
7390,
45,
22
]
],
[
[
1302,
21,
28730
],
[
28730,
60,
22
]
],
[
[
1302,
63,
475
],
[
475,
... | [
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ephedrine"
]
],
[
[
"Protriptyline",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",
"Ep... | Protriptyline (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Ephedrine (Compound)
Protriptyline (Compound) causes Psychotic disorder (Side Effect) and Psychotic disorder (Side Effect) is caused by Ephedrine (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken... |
DB00196 | DB08932 | 600 | 1,398 | [
"DDInter743",
"DDInter1111"
] | Fluconazole | Macitentan | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Moderate | 1 | [
[
[
600,
24,
1398
]
],
[
[
600,
6,
8374
],
[
8374,
45,
1398
]
],
[
[
600,
21,
29429
],
[
29429,
60,
1398
]
],
[
[
600,
24,
283
],
[
283,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Macitentan (Compound)
Fluconazole (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Macitentan (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fedr... |
DB06168 | DB13985 | 1,531 | 546 | [
"DDInter281",
"DDInter1108"
] | Canakinumab | Lutetium Lu 177 dotatate | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Moderate | 1 | [
[
[
1531,
24,
546
]
],
[
[
1531,
63,
66
],
[
66,
24,
546
]
],
[
[
1531,
24,
270
],
[
270,
24,
546
]
],
[
[
1531,
64,
1057
],
[
1057,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrel... |
DB00204 | DB12332 | 228 | 1,619 | [
"DDInter580",
"DDInter1626"
] | Dofetilide | Rucaparib | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
228,
25,
1619
]
],
[
[
228,
23,
112
],
[
112,
23,
1619
]
],
[
[
228,
25,
1662
],
[
1662,
24,
1619
]
],
[
[
228,
24,
1419
],
[
1419,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Dofetilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Dofetilide may lead to a major life threatening interaction when taken with Picosulfuric acid and Picosulfuric ... |
DB00046 | DB00860 | 1,179 | 891 | [
"DDInter940",
"DDInter1513"
] | Insulin lispro | Prednisolone | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1179,
24,
891
]
],
[
[
1179,
24,
989
],
[
989,
1,
891
]
],
[
[
1179,
24,
175
],
[
175,
40,
891
]
],
[
[
1179,
24,
1561
],
[
1561,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Progesterone"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Prednisolone (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Pr... |
DB06209 | DB11793 | 256 | 738 | [
"DDInter1508",
"DDInter1297"
] | Prasugrel | Niraparib | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
256,
24,
738
]
],
[
[
256,
64,
1213
],
[
1213,
24,
738
]
],
[
[
256,
25,
1598
],
[
1598,
63,
738
]
],
[
[
256,
25,
397
],
[
397,
... | [
[
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Prasugrel may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Prasugrel may lead to a major life threatening interaction when taken with Tazemetostat and Tazemetostat may cause a moderate inter... |
DB00719 | DB00813 | 1,219 | 704 | [
"DDInter149",
"DDInter722"
] | Azatadine | Fentanyl | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Moderate | 1 | [
[
[
1219,
24,
704
]
],
[
[
1219,
63,
194
],
[
194,
40,
704
]
],
[
[
1219,
24,
543
],
[
543,
1,
704
]
],
[
[
1219,
24,
1322
],
[
1322,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Fentanyl (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide (Compound) resembles Fentanyl (Compound)
Azat... |
DB01224 | DB01409 | 623 | 1,415 | [
"DDInter1553",
"DDInter1815"
] | Quetiapine | Tiotropium | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
623,
24,
1415
]
],
[
[
623,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
623,
21,
29187
],
[
29187,
60,
1415
]
],
[
[
623,
62,
752
],
[
752,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Quetiapine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
... | Quetiapine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Quetiapine (Compound) causes Rhinitis (Side Effect) and Rhinitis (Side Effect) is caused by Tiotropium (Compound)
Quetiapine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine... |
DB00748 | DB01186 | 662 | 107 | [
"DDInter297",
"DDInter1430"
] | Carbinoxamine | Pergolide | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | Moderate | 1 | [
[
[
662,
24,
107
]
],
[
[
662,
6,
12523
],
[
12523,
45,
107
]
],
[
[
662,
18,
4717
],
[
4717,
57,
107
]
],
[
[
662,
21,
28757
],
[
28757,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compou... | Carbinoxamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pergolide (Compound)
Carbinoxamine (Compound) downregulates RTN2 (Gene) and RTN2 (Gene) is downregulated by Pergolide (Compound)
Carbinoxamine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Pergolide (Compound... |
DB00708 | DB11718 | 1,454 | 927 | [
"DDInter1718",
"DDInter640"
] | Sufentanil | Encorafenib | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1454,
24,
927
]
],
[
[
1454,
24,
1264
],
[
1264,
24,
927
]
],
[
[
1454,
1,
1322
],
[
1322,
24,
927
]
],
[
[
1454,
24,
1259
],
[
1259,
... | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Sufentanil (Compound) resembles Alfentanil (Compound) and Alfentanil may cause a moderate interaction that could exac... |
DB00675 | DB00731 | 888 | 1,144 | [
"DDInter1744",
"DDInter1269"
] | Tamoxifen | Nateglinide | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
888,
24,
1144
]
],
[
[
888,
6,
6799
],
[
6799,
45,
1144
]
],
[
[
888,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
888,
24,
804
],
[
804,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Tamoxifen",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compound)",
... | Tamoxifen (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Nateglinide (Compound)
Tamoxifen (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone and... |
DB01268 | DB09020 | 1,151 | 28 | [
"DDInter1731",
"DDInter212"
] | Sunitinib | Bisacodyl | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
1151,
24,
28
]
],
[
[
1151,
6,
6994
],
[
6994,
46,
28
]
],
[
[
1151,
18,
4071
],
[
4071,
46,
28
]
],
[
[
1151,
7,
13230
],
[
13230,
... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Sunitinib",
"{u} (Compound) binds {v} (Gene)",
"STK17B"
],
[
"STK17B",
"{u} (Gene) is upregulated by {v} (Compound... | Sunitinib (Compound) binds STK17B (Gene) and STK17B (Gene) is upregulated by Bisacodyl (Compound)
Sunitinib (Compound) downregulates PNP (Gene) and PNP (Gene) is upregulated by Bisacodyl (Compound)
Sunitinib (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Bisacodyl (Compound)
Sunitinib (Compoun... |
DB00072 | DB00694 | 550 | 51 | [
"DDInter1846",
"DDInter485"
] | Trastuzumab | Daunorubicin | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Major | 2 | [
[
[
550,
25,
51
]
],
[
[
550,
24,
1430
],
[
1430,
63,
51
]
],
[
[
550,
24,
58
],
[
58,
24,
51
]
],
[
[
550,
63,
1253
],
[
1253,
24,
... | [
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daunorubicin"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipu... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and... |
DB01144 | DB09043 | 1,326 | 135 | [
"DDInter540",
"DDInter36"
] | Diclofenamide | Albiglutide | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1326,
24,
135
]
],
[
[
1326,
63,
1647
],
[
1647,
23,
135
]
],
[
[
1326,
63,
870
],
[
870,
24,
135
]
],
[
[
1326,
1,
359
],
[
359,
... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and ... |
DB00819 | DB09080 | 471 | 144 | [
"DDInter15",
"DDInter1331"
] | Acetazolamide | Olodaterol | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
471,
24,
144
]
],
[
[
471,
25,
57
],
[
57,
24,
144
]
],
[
[
471,
63,
1324
],
[
1324,
24,
144
]
],
[
[
471,
23,
1264
],
[
1264,
2... | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Acetazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Acetazolamide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and T... |
DB00472 | DB06754 | 758 | 707 | [
"DDInter758",
"DDInter471"
] | Fluoxetine | Danaparoid | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Moderate | 1 | [
[
[
758,
24,
707
]
],
[
[
758,
25,
121
],
[
121,
24,
707
]
],
[
[
758,
24,
1151
],
[
1151,
24,
707
]
],
[
[
758,
1,
109
],
[
109,
24... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
],
[
"Fenflura... | Fluoxetine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may caus... |
DB01246 | DB04953 | 820 | 495 | [
"DDInter45",
"DDInter708"
] | Alimemazine | Ezogabine | A phenothiazine derivative that is used as an antipruritic. | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
820,
24,
495
]
],
[
[
820,
21,
28787
],
[
28787,
60,
495
]
],
[
[
820,
62,
112
],
[
112,
23,
495
]
],
[
[
820,
63,
1494
],
[
1494,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Alimemazine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is c... | Alimemazine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ezogabine (Compound)
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ez... |
DB00563 | DB14006 | 663 | 972 | [
"DDInter1174",
"DDInter370"
] | Methotrexate | Choline salicylate | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Major | 2 | [
[
[
663,
25,
972
]
],
[
[
663,
25,
660
],
[
660,
23,
972
]
],
[
[
663,
64,
837
],
[
837,
23,
972
]
],
[
[
663,
24,
1573
],
[
1573,
2... | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Choline salicylate"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazol... | Methotrexate may lead to a major life threatening interaction when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Choline salicylate
Methotrexate may lead to a major life threatening interaction when taken with Pantoprazole and Pantoprazole may cau... |
DB00726 | DB01254 | 1,164 | 1,213 | [
"DDInter1876",
"DDInter484"
] | Trimipramine | Dasatinib | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
1164,
24,
1213
]
],
[
[
1164,
6,
4973
],
[
4973,
45,
1213
]
],
[
[
1164,
7,
1986
],
[
1986,
46,
1213
]
],
[
[
1164,
18,
15501
],
[
155... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Trimipramine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)"... | Trimipramine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound)
Trimipramine (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Dasatinib (Compound)
Trimipramine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Dasatinib (Compound)
Trimipram... |
DB00738 | DB06655 | 485 | 5 | [
"DDInter1420",
"DDInter1077"
] | Pentamidine | Liraglutide | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
485,
24,
5
]
],
[
[
485,
63,
245
],
[
245,
24,
5
]
],
[
[
485,
24,
1630
],
[
1630,
24,
5
]
],
[
[
485,
24,
1296
],
[
1296,
63,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and... |
DB06650 | DB10795 | 1,500 | 221 | [
"DDInter1324",
"DDInter1486"
] | Ofatumumab | Poliovirus type 1 antigen (formaldehyde inactivated) | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
1500,
24,
221
]
],
[
[
1500,
64,
581
],
[
581,
24,
221
]
],
[
[
1500,
63,
599
],
[
599,
24,
221
]
],
[
[
1500,
25,
1510
],
[
1510,
... | [
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"... | Ofatumumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken... |
DB00945 | DB10672 | 1,479 | 297 | [
"DDInter20",
"DDInter417"
] | Acetylsalicylic acid | Clove | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Clove allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
1479,
23,
297
]
],
[
[
1479,
25,
235
],
[
235,
62,
297
]
],
[
[
1479,
24,
578
],
[
578,
23,
297
]
],
[
[
1479,
25,
1564
],
[
1564,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
... | Acetylsalicylic acid may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor... |
DB00701 | DB01276 | 1,091 | 123 | [
"DDInter90",
"DDInter706"
] | Amprenavir | Exenatide | Amprenavir is a protease inhibitor used to treat HIV infection. | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1091,
24,
123
]
],
[
[
1091,
25,
1476
],
[
1476,
63,
123
]
],
[
[
1091,
63,
1573
],
[
1573,
24,
123
]
],
[
[
1091,
24,
1040
],
[
1040,... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib"... | Amprenavir may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a... |
DB00549 | DB00912 | 522 | 473 | [
"DDInter1955",
"DDInter1581"
] | Zafirlukast | Repaglinide | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
522,
24,
473
]
],
[
[
522,
6,
3486
],
[
3486,
45,
473
]
],
[
[
522,
21,
28757
],
[
28757,
60,
473
]
],
[
[
522,
24,
311
],
[
311,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound... | Zafirlukast (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Repaglinide (Compound)
Zafirlukast (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Repaglinide (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib and... |
DB00418 | DB06626 | 536 | 263 | [
"DDInter1650",
"DDInter147"
] | Secobarbital | Axitinib | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Moderate | 1 | [
[
[
536,
24,
263
]
],
[
[
536,
23,
752
],
[
752,
23,
263
]
],
[
[
536,
24,
392
],
[
392,
24,
263
]
],
[
[
536,
24,
1593
],
[
1593,
6... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Secobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
... | Secobarbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Axitinib
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib... |
DB09389 | DB13874 | 517 | 1,501 | [
"DDInter1315",
"DDInter639"
] | Norgestrel | Enasidenib | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible ... | Moderate | 1 | [
[
[
517,
24,
1501
]
],
[
[
517,
24,
1619
],
[
1619,
24,
1501
]
],
[
[
517,
64,
1604
],
[
1604,
24,
1501
]
],
[
[
517,
63,
473
],
[
473,
... | [
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
]
],
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Norgestrel may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a ... |
DB06016 | DB09043 | 1,508 | 135 | [
"DDInter300",
"DDInter36"
] | Cariprazine | Albiglutide | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1508,
24,
135
]
],
[
[
1508,
63,
1647
],
[
1647,
23,
135
]
],
[
[
1508,
63,
176
],
[
176,
24,
135
]
],
[
[
1508,
64,
609
],
[
609,
... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Ins... |
DB06372 | DB08885 | 259 | 363 | [
"DDInter1594",
"DDInter33"
] | Rilonacept | Aflibercept | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Moderate | 1 | [
[
[
259,
24,
363
]
],
[
[
259,
63,
1531
],
[
1531,
24,
363
]
],
[
[
259,
24,
151
],
[
151,
63,
363
]
],
[
[
259,
24,
1136
],
[
1136,
... | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aflibercept"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
... | Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus ... |
DB00056 | DB09061 | 816 | 1,627 | [
"DDInter814",
"DDInter284"
] | Gemtuzumab ozogamicin | Cannabidiol | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
816,
24,
1627
]
],
[
[
816,
24,
384
],
[
384,
23,
1627
]
],
[
[
816,
24,
1613
],
[
1613,
63,
1627
]
],
[
[
816,
24,
267
],
[
267,
... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idel... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB01263 | DB05294 | 859 | 1,069 | [
"DDInter1494",
"DDInter1917"
] | Posaconazole | Vandetanib | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
859,
25,
1069
]
],
[
[
859,
63,
1195
],
[
1195,
40,
1069
]
],
[
[
859,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
859,
21,
29343
],
[
29343,... | [
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotin... | Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) resembles Vandetanib (Compound)
Posaconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Posaconazole (Compound) causes Blood creatinine increased (Side ... |
DB00472 | DB00569 | 758 | 553 | [
"DDInter758",
"DDInter775"
] | Fluoxetine | Fondaparinux | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Moderate | 1 | [
[
[
758,
24,
553
]
],
[
[
758,
21,
28681
],
[
28681,
60,
553
]
],
[
[
758,
1,
109
],
[
109,
24,
553
]
],
[
[
758,
25,
222
],
[
222,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fondaparinux"
]
],
[
[
"Fluoxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side... | Fluoxetine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Fondaparinux (Compound)
Fluoxetine (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Fondaparinux
Fluoxetine may lead to a m... |
DB00777 | DB01612 | 146 | 1,637 | [
"DDInter1537",
"DDInter92"
] | Propiomazine | Amyl Nitrite | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
146,
24,
1637
]
],
[
[
146,
64,
475
],
[
475,
24,
1637
]
],
[
[
146,
24,
401
],
[
401,
24,
1637
]
],
[
[
146,
25,
593
],
[
593,
... | [
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Propiomazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphi... | Propiomazine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may ... |
DB11921 | DB12887 | 1,019 | 1,598 | [
"DDInter492",
"DDInter1750"
] | Deflazacort | Tazemetostat | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
1019,
24,
1598
]
],
[
[
1019,
63,
1324
],
[
1324,
24,
1598
]
],
[
[
1019,
24,
1619
],
[
1619,
24,
1598
]
],
[
[
1019,
24,
159
],
[
159... | [
[
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and... |
DB00957 | DB08880 | 873 | 1,510 | [
"DDInter1314",
"DDInter1771"
] | Norgestimate | Teriflunomide | Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat mod... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Moderate | 1 | [
[
[
873,
24,
1510
]
],
[
[
873,
24,
1406
],
[
1406,
63,
1510
]
],
[
[
873,
40,
1197
],
[
1197,
24,
1510
]
],
[
[
873,
25,
927
],
[
927,
... | [
[
[
"Norgestimate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Norgestimate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
],
... | Norgestimate may cause a moderate interaction that could exacerbate diseases when taken with Neratinib and Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Norgestimate (Compound) resembles Norethisterone (Compound) and Norethisterone may cause a moderate interacti... |
DB00241 | DB00501 | 288 | 752 | [
"DDInter257",
"DDInter380"
] | Butalbital | Cimetidine | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Minor | 0 | [
[
[
288,
23,
752
]
],
[
[
288,
24,
112
],
[
112,
62,
752
]
],
[
[
288,
24,
542
],
[
542,
23,
752
]
],
[
[
288,
63,
1331
],
[
1331,
2... | [
[
[
"Butalbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and... |
DB00031 | DB00063 | 20 | 366 | [
"DDInter1764",
"DDInter659"
] | Tenecteplase | Eptifibatide | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Major | 2 | [
[
[
20,
25,
366
]
],
[
[
20,
23,
944
],
[
944,
62,
366
]
],
[
[
20,
24,
311
],
[
311,
63,
366
]
],
[
[
20,
24,
1595
],
[
1595,
24,
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
]
],
[
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomi... | Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Eptifibatide
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib and Valdec... |
DB00514 | DB04844 | 506 | 843 | [
"DDInter527",
"DDInter1778"
] | Dextromethorphan | Tetrabenazine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
506,
24,
843
]
],
[
[
506,
6,
12523
],
[
12523,
45,
843
]
],
[
[
506,
18,
5901
],
[
5901,
57,
843
]
],
[
[
506,
21,
29093
],
[
29093,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {... | Dextromethorphan (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Dextromethorphan (Compound) downregulates GJA1 (Gene) and GJA1 (Gene) is downregulated by Tetrabenazine (Compound)
Dextromethorphan (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Tetrab... |
DB06616 | DB11732 | 594 | 1,097 | [
"DDInter224",
"DDInter1027"
] | Bosutinib | Lasmiditan | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
594,
24,
1097
]
],
[
[
594,
63,
1181
],
[
1181,
24,
1097
]
],
[
[
594,
24,
971
],
[
971,
63,
1097
]
],
[
[
594,
25,
384
],
[
384,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilt... |
DB00694 | DB11853 | 51 | 230 | [
"DDInter485",
"DDInter1577"
] | Daunorubicin | Relugolix | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
51,
24,
230
]
],
[
[
51,
24,
129
],
[
129,
23,
230
]
],
[
[
51,
23,
112
],
[
112,
23,
230
]
],
[
[
51,
24,
1476
],
[
1476,
62,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and ... |
DB01357 | DB06777 | 890 | 780 | [
"DDInter1160",
"DDInter348"
] | Mestranol | Chenodeoxycholic acid | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decre... | Moderate | 1 | [
[
[
890,
24,
780
]
],
[
[
890,
1,
380
],
[
380,
24,
780
]
],
[
[
890,
63,
126
],
[
126,
24,
780
]
],
[
[
890,
40,
559
],
[
559,
24,
... | [
[
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
... | Mestranol (Compound) resembles Conjugated estrogens (Compound) and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Chenodeoxycholic acid
Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a modera... |
DB08820 | DB12674 | 1,478 | 975 | [
"DDInter997",
"DDInter1105"
] | Ivacaftor | Lurbinectedin | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
1478,
24,
975
]
],
[
[
1478,
24,
1613
],
[
1613,
24,
975
]
],
[
[
1478,
24,
159
],
[
159,
63,
975
]
],
[
[
1478,
63,
372
],
[
372,
... | [
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
... | Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01021 | DB01050 | 674 | 848 | [
"DDInter1861",
"DDInter900"
] | Trichlormethiazide | Ibuprofen | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
674,
24,
848
]
],
[
[
674,
24,
1053
],
[
1053,
1,
848
]
],
[
[
674,
24,
286
],
[
286,
62,
848
]
],
[
[
674,
40,
178
],
[
178,
63... | [
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine... | Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may ca... |
DB00865 | DB06655 | 939 | 5 | [
"DDInter187",
"DDInter1077"
] | Benzphetamine | Liraglutide | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
939,
24,
5
]
],
[
[
939,
63,
245
],
[
245,
24,
5
]
],
[
[
939,
24,
480
],
[
480,
24,
5
]
],
[
[
939,
64,
73
],
[
73,
24,
5... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol a... |
DB00619 | DB01004 | 1,419 | 563 | [
"DDInter909",
"DDInter806"
] | Imatinib | Ganciclovir | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
1419,
24,
563
]
],
[
[
1419,
24,
248
],
[
248,
40,
563
]
],
[
[
1419,
6,
10715
],
[
10715,
45,
563
]
],
[
[
1419,
21,
29233
],
[
29233... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Imatinib (Compound) binds SLC22A1 (Gene) and SLC22A1 (Gene) is bound by Ganciclovir (Compound)
Imatinib (Compound) causes Creatinine increased (Side Effe... |
DB00328 | DB12015 | 831 | 1,033 | [
"DDInter921",
"DDInter53"
] | Indomethacin | Alpelisib | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
831,
24,
1033
]
],
[
[
831,
24,
738
],
[
738,
24,
1033
]
],
[
[
831,
25,
1510
],
[
1510,
24,
1033
]
],
[
[
831,
24,
1619
],
[
1619,
... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
... | Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Indomethacin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may... |
DB00420 | DB00741 | 508 | 167 | [
"DDInter1532",
"DDInter885"
] | Promazine | Hydrocortisone | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
508,
24,
167
]
],
[
[
508,
24,
870
],
[
870,
1,
167
]
],
[
[
508,
6,
8374
],
[
8374,
45,
167
]
],
[
[
508,
7,
3163
],
[
3163,
46... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Hydrocortisone (Compound)
Promazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Hydrocortisone (Compound)
Promazine (Compound) upregulates TSC22D3 (Gene) an... |
DB00681 | DB01135 | 1,287 | 648 | [
"DDInter85",
"DDInter590"
] | Amphotericin B | Doxacurium | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration. | Moderate | 1 | [
[
[
1287,
24,
648
]
],
[
[
1287,
24,
1319
],
[
1319,
40,
648
]
],
[
[
1287,
63,
251
],
[
251,
24,
648
]
],
[
[
1287,
24,
1486
],
[
1486,
... | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxacurium"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mivacurium"
],
... | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Mivacurium and Mivacurium (Compound) resembles Doxacurium (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interact... |
DB00661 | DB01190 | 122 | 568 | [
"DDInter1928",
"DDInter398"
] | Verapamil | Clindamycin | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Moderate | 1 | [
[
[
122,
24,
568
]
],
[
[
122,
6,
8374
],
[
8374,
45,
568
]
],
[
[
122,
21,
28680
],
[
28680,
60,
568
]
],
[
[
122,
24,
609
],
[
609,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clindamycin"
]
],
[
[
"Verapamil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Verapamil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clindamycin (Compound)
Verapamil (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Clindamycin (Compound)
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromy... |
DB00783 | DB01309 | 1,438 | 1,254 | [
"DDInter679",
"DDInter933"
] | Estradiol | Insulin glulisine | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
1438,
24,
1254
]
],
[
[
1438,
63,
167
],
[
167,
24,
1254
]
],
[
[
1438,
24,
1220
],
[
1220,
24,
1254
]
],
[
[
1438,
1,
35
],
[
35,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Dexameth... |
DB00776 | DB11837 | 1,335 | 1,297 | [
"DDInter1360",
"DDInter1351"
] | Oxcarbazepine | Osilodrostat | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
1335,
24,
1297
]
],
[
[
1335,
24,
1135
],
[
1135,
23,
1297
]
],
[
[
1335,
24,
466
],
[
466,
62,
1297
]
],
[
[
1335,
24,
1320
],
[
1320... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and ... |
DB00635 | DB00691 | 1,573 | 1,058 | [
"DDInter1515",
"DDInter1237"
] | Prednisone | Moexipril | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Moderate | 1 | [
[
[
1573,
24,
1058
]
],
[
[
1573,
63,
1638
],
[
1638,
1,
1058
]
],
[
[
1573,
24,
743
],
[
743,
1,
1058
]
],
[
[
1573,
24,
954
],
[
954,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moexipril"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Moexipril (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril (Compound) resembles Moexipril (Compound... |
DB01309 | DB06203 | 1,254 | 1,002 | [
"DDInter933",
"DDInter51"
] | Insulin glulisine | Alogliptin | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
1254,
24,
1002
]
],
[
[
1254,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
1254,
62,
1103
],
[
1103,
23,
1002
]
],
[
[
1254,
63,
504
],
[
504... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Insulin glulisine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction... |
DB06603 | DB09034 | 39 | 1,313 | [
"DDInter1387",
"DDInter1733"
] | Panobinostat | Suvorexant | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
39,
24,
1313
]
],
[
[
39,
64,
1213
],
[
1213,
24,
1313
]
],
[
[
39,
25,
1619
],
[
1619,
63,
1313
]
],
[
[
39,
63,
353
],
[
353,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatin... | Panobinostat may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Panobinostat may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate inte... |
DB06282 | DB09034 | 516 | 1,313 | [
"DDInter1053",
"DDInter1733"
] | Levocetirizine | Suvorexant | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
516,
24,
1313
]
],
[
[
516,
63,
649
],
[
649,
24,
1313
]
],
[
[
516,
24,
849
],
[
849,
24,
1313
]
],
[
[
516,
24,
407
],
[
407,
... | [
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine an... |
DB04855 | DB08881 | 540 | 868 | [
"DDInter602",
"DDInter1925"
] | Dronedarone | Vemurafenib | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
540,
25,
868
]
],
[
[
540,
6,
8374
],
[
8374,
45,
868
]
],
[
[
540,
21,
28714
],
[
28714,
60,
868
]
],
[
[
540,
63,
608
],
[
608,
... | [
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Dronedarone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemu... | Dronedarone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Dronedarone (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Vemurafenib (Compound)
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Li... |
DB00982 | DB09122 | 1,517 | 1,613 | [
"DDInter991",
"DDInter1409"
] | Isotretinoin | Peginterferon beta-1a | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1517,
24,
1613
]
],
[
[
1517,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
1517,
63,
362
],
[
362,
24,
1613
]
],
[
[
1517,
24,
214
],
[
214,
... | [
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"... | Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Phen... |
DB01064 | DB11853 | 1,148 | 230 | [
"DDInter987",
"DDInter1577"
] | Isoprenaline | Relugolix | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
1148,
24,
230
]
],
[
[
1148,
24,
129
],
[
129,
23,
230
]
],
[
[
1148,
63,
480
],
[
480,
24,
230
]
],
[
[
1148,
24,
1213
],
[
1213,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and F... |
DB06203 | DB15093 | 1,002 | 1,654 | [
"DDInter51",
"DDInter1698"
] | Alogliptin | Somapacitan | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1002,
24,
1654
]
],
[
[
1002,
63,
168
],
[
168,
23,
1654
]
],
[
[
1002,
63,
176
],
[
176,
24,
1654
]
],
[
[
1002,
24,
1019
],
[
1019,
... | [
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and I... |
DB00418 | DB00719 | 536 | 1,219 | [
"DDInter1650",
"DDInter149"
] | Secobarbital | Azatadine | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
536,
24,
1219
]
],
[
[
536,
24,
13
],
[
13,
24,
1219
]
],
[
[
536,
24,
830
],
[
830,
1,
1219
]
],
[
[
536,
24,
1376
],
[
1376,
6... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Phenindami... |
DB00081 | DB00991 | 273 | 97 | [
"DDInter1838",
"DDInter1358"
] | Tositumomab | Oxaprozin | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Major | 2 | [
[
[
273,
25,
97
]
],
[
[
273,
37,
1274
],
[
1274,
24,
97
]
],
[
[
273,
25,
936
],
[
936,
63,
97
]
],
[
[
273,
64,
582
],
[
582,
24,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaprozin"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening inter... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Tositumomab may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Tositumomab ma... |
DB00526 | DB08865 | 1,555 | 1,593 | [
"DDInter1355",
"DDInter448"
] | Oxaliplatin | Crizotinib | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1555,
25,
1593
]
],
[
[
1555,
24,
479
],
[
479,
23,
1593
]
],
[
[
1555,
23,
1247
],
[
1247,
23,
1593
]
],
[
[
1555,
24,
1627
],
[
1627... | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulf... |
DB00682 | DB00939 | 126 | 1,338 | [
"DDInter1951",
"DDInter1135"
] | Warfarin | Meclofenamic acid | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Major | 2 | [
[
[
126,
25,
1338
]
],
[
[
126,
1,
345
],
[
345,
1,
1338
]
],
[
[
126,
25,
1479
],
[
1479,
63,
1338
]
],
[
[
126,
24,
1194
],
[
1194,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound)",
"Salsalate"
],
[
"Salsalate",
"{u} (Compound) resembles {v} (Compoun... | Warfarin (Compound) resembles Salsalate (Compound) and Salsalate (Compound) resembles Meclofenamic acid (Compound)
Warfarin may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclo... |
DB00526 | DB06317 | 1,555 | 1,626 | [
"DDInter1355",
"DDInter630"
] | Oxaliplatin | Elotuzumab | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
1555,
24,
1626
]
],
[
[
1555,
24,
973
],
[
973,
24,
1626
]
],
[
[
1555,
63,
1463
],
[
1463,
24,
1626
]
],
[
[
1555,
24,
200
],
[
200,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lova... |
DB00675 | DB04865 | 888 | 4 | [
"DDInter1744",
"DDInter1335"
] | Tamoxifen | Omacetaxine mepesuccinate | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
888,
24,
4
]
],
[
[
888,
7,
14560
],
[
14560,
46,
4
]
],
[
[
888,
18,
7623
],
[
7623,
46,
4
]
],
[
[
888,
6,
9842
],
[
9842,
46,... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Tamoxifen",
"{u} (Compound) upregulates {v} (Gene)",
"STAP2"
],
[
"STAP2",
"{u} (Gene) is upregula... | Tamoxifen (Compound) upregulates STAP2 (Gene) and STAP2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Tamoxifen (Compound) downregulates RRP12 (Gene) and RRP12 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Tamoxifen (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is upregulated by Omace... |
DB00405 | DB00835 | 128 | 100 | [
"DDInter517",
"DDInter245"
] | Dexbrompheniramine | Brompheniramine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
128,
24,
100
]
],
[
[
128,
24,
832
],
[
832,
24,
100
]
],
[
[
128,
1,
11786
],
[
11786,
40,
100
]
],
[
[
128,
40,
11244
],
[
11244,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripel... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Dexbrompheniramine (Compound) resembles Captodiame (Compound) and Captodiame (Compound) res... |
DB00491 | DB00865 | 127 | 939 | [
"DDInter1217",
"DDInter187"
] | Miglitol | Benzphetamine | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Moderate | 1 | [
[
[
127,
24,
939
]
],
[
[
127,
24,
1529
],
[
1529,
1,
939
]
],
[
[
127,
63,
508
],
[
508,
1,
939
]
],
[
[
127,
24,
401
],
[
401,
63,... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Benzphetamine (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Benzphetamine (Comp... |
DB00867 | DB06788 | 1,052 | 1,616 | [
"DDInter1606",
"DDInter864"
] | Ritodrine | Histrelin | Adrenergic beta-agonist used to control premature labor. | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
1052,
24,
1616
]
],
[
[
1052,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
1052,
63,
1179
],
[
1179,
24,
1616
]
],
[
[
1052,
24,
927
],
[
927... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insul... |
DB00108 | DB10989 | 1,066 | 496 | [
"DDInter1268",
"DDInter858"
] | Natalizumab | Hepatitis A Vaccine | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
1066,
24,
496
]
],
[
[
1066,
25,
1093
],
[
1093,
63,
496
]
],
[
[
1066,
25,
4
],
[
4,
24,
496
]
],
[
[
1066,
64,
1560
],
[
1560,
... | [
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
],
[
... | Natalizumab may lead to a major life threatening interaction when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Natalizumab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxin... |
DB00531 | DB00673 | 450 | 723 | [
"DDInter456",
"DDInter112"
] | Cyclophosphamide | Aprepitant | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
450,
24,
723
]
],
[
[
450,
24,
875
],
[
875,
40,
723
]
],
[
[
450,
6,
6799
],
[
6799,
45,
723
]
],
[
[
450,
21,
28890
],
[
28890,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Cyclophosphamide (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Aprepitant (Compound)
Cyclophosphamide (Compound) causes Myocardial in... |
DB00377 | DB00850 | 1,494 | 1,630 | [
"DDInter1382",
"DDInter1432"
] | Palonosetron | Perphenazine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Moderate | 1 | [
[
[
1494,
24,
1630
]
],
[
[
1494,
24,
252
],
[
252,
40,
1630
]
],
[
[
1494,
25,
827
],
[
827,
40,
1630
]
],
[
[
1494,
6,
12523
],
[
12523,... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],
... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Perphenazine (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Trazodone and Trazodone (Compound) resembles Perphenazine (Compound)
Palonos... |
DB00549 | DB15822 | 522 | 69 | [
"DDInter1955",
"DDInter1504"
] | Zafirlukast | Pralsetinib | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
522,
24,
69
]
],
[
[
522,
24,
985
],
[
985,
24,
69
]
],
[
[
522,
63,
322
],
[
322,
24,
69
]
],
[
[
522,
24,
129
],
[
129,
25,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and E... |
DB00283 | DB06700 | 701 | 643 | [
"DDInter395",
"DDInter511"
] | Clemastine | Desvenlafaxine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
701,
24,
643
]
],
[
[
701,
24,
1100
],
[
1100,
1,
643
]
],
[
[
701,
6,
8374
],
[
8374,
45,
643
]
],
[
[
701,
21,
28709
],
[
28709,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Desvenlafaxine (Compound)
Clemastine (Compound) causes Decreased appetite (Side Ef... |
DB00262 | DB08895 | 552 | 976 | [
"DDInter302",
"DDInter1825"
] | Carmustine | Tofacitinib | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
552,
25,
976
]
],
[
[
552,
63,
1461
],
[
1461,
23,
976
]
],
[
[
552,
24,
200
],
[
200,
63,
976
]
],
[
[
552,
24,
1252
],
[
1252,
... | [
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E"... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Can... |
DB01218 | DB08868 | 1,493 | 1,011 | [
"DDInter852",
"DDInter737"
] | Halofantrine | Fingolimod | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1493,
25,
1011
]
],
[
[
1493,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
1493,
21,
28714
],
[
28714,
60,
1011
]
],
[
[
1493,
62,
1247
],
[
... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Halofantrine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fin... | Halofantrine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Halofantrine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Fingolimod (Compound)
Halofantrine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole ... |
DB00444 | DB00649 | 63 | 231 | [
"DDInter1765",
"DDInter1710"
] | Teniposide | Stavudine | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Moderate | 1 | [
[
[
63,
24,
231
]
],
[
[
63,
24,
1477
],
[
1477,
40,
231
]
],
[
[
63,
24,
139
],
[
139,
1,
231
]
],
[
[
63,
18,
6351
],
[
6351,
57,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stavudine"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine (Compound) resembles Stavudine (Compound)
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Stavudine (Compound)
... |
DB00358 | DB04948 | 1,010 | 1,084 | [
"DDInter1140",
"DDInter1083"
] | Mefloquine | Lofexidine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
1010,
24,
1084
]
],
[
[
1010,
23,
112
],
[
112,
23,
1084
]
],
[
[
1010,
63,
618
],
[
618,
24,
1084
]
],
[
[
1010,
24,
774
],
[
774,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarel... |
DB00867 | DB09045 | 1,052 | 52 | [
"DDInter1606",
"DDInter607"
] | Ritodrine | Dulaglutide | Adrenergic beta-agonist used to control premature labor. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
1052,
24,
52
]
],
[
[
1052,
24,
170
],
[
170,
23,
52
]
],
[
[
1052,
24,
609
],
[
609,
24,
52
]
],
[
[
1052,
63,
73
],
[
73,
24,
... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Cla... |
DB00026 | DB00056 | 1,184 | 816 | [
"DDInter94",
"DDInter814"
] | Anakinra | Gemtuzumab ozogamicin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Moderate | 1 | [
[
[
1184,
24,
816
]
],
[
[
1184,
63,
305
],
[
305,
24,
816
]
],
[
[
1184,
24,
869
],
[
869,
63,
816
]
],
[
[
1184,
25,
676
],
[
676,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemtuzumab ozogamicin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escheri... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Gemtuzumab ozogamicin
Anakinra may cause a moderate interaction that could exacerbate d... |
DB01076 | DB11837 | 700 | 1,297 | [
"DDInter133",
"DDInter1351"
] | Atorvastatin | Osilodrostat | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
700,
24,
1297
]
],
[
[
700,
63,
112
],
[
112,
23,
1297
]
],
[
[
700,
24,
466
],
[
466,
62,
1297
]
],
[
[
700,
24,
1320
],
[
1320,
... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamid... |
DB00969 | DB12332 | 2 | 1,619 | [
"DDInter52",
"DDInter1626"
] | Alosetron | Rucaparib | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
2,
24,
1619
]
],
[
[
2,
24,
1362
],
[
1362,
24,
1619
]
],
[
[
2,
63,
215
],
[
215,
24,
1619
]
],
[
[
2,
24,
68
],
[
68,
63,
... | [
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"... | Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir may ... |
DB01089 | DB09564 | 1,340 | 1,296 | [
"DDInter502",
"DDInter930"
] | Deserpidine | Insulin degludec | Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1340,
24,
1296
]
],
[
[
1340,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1340,
63,
401
],
[
401,
24,
1296
]
],
[
[
1340,
24,
1019
],
[
1019... | [
[
[
"Deserpidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Deserpidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],... | Deserpidine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Deserpidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazin... |
DB00641 | DB01211 | 467 | 609 | [
"DDInter1675",
"DDInter393"
] | Simvastatin | Clarithromycin | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Major | 2 | [
[
[
467,
25,
609
]
],
[
[
467,
63,
1570
],
[
1570,
24,
609
]
],
[
[
467,
6,
4973
],
[
4973,
45,
609
]
],
[
[
467,
7,
3466
],
[
3466,
... | [
[
[
"Simvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
"Az... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Simvastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Simvas... |
DB00532 | DB01233 | 208 | 1,311 | [
"DDInter1152",
"DDInter1197"
] | Mephenytoin | Metoclopramide | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
208,
24,
1311
]
],
[
[
208,
63,
1010
],
[
1010,
23,
1311
]
],
[
[
208,
24,
649
],
[
649,
63,
1311
]
],
[
[
208,
24,
662
],
[
662,
... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metoclopramide
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Cl... |
DB00283 | DB01409 | 701 | 1,415 | [
"DDInter395",
"DDInter1815"
] | Clemastine | Tiotropium | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
701,
24,
1415
]
],
[
[
701,
6,
8374
],
[
8374,
45,
1415
]
],
[
[
701,
21,
28722
],
[
28722,
60,
1415
]
],
[
[
701,
24,
146
],
[
146,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Clemastine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tiotropium (Compound)
Clemastine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Tiotropium (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propioma... |
DB00208 | DB06228 | 1,018 | 792 | [
"DDInter1804",
"DDInter1609"
] | Ticlopidine | Rivaroxaban | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Major | 2 | [
[
[
1018,
25,
792
]
],
[
[
1018,
6,
8374
],
[
8374,
45,
792
]
],
[
[
1018,
21,
28703
],
[
28703,
60,
792
]
],
[
[
1018,
23,
944
],
[
944,
... | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Riva... | Ticlopidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rivaroxaban (Compound)
Ticlopidine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Rivaroxaban (Compound)
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Chamomile and Cham... |
DB00631 | DB00641 | 372 | 467 | [
"DDInter405",
"DDInter1675"
] | Clofarabine | Simvastatin | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Moderate | 1 | [
[
[
372,
24,
467
]
],
[
[
372,
18,
4519
],
[
4519,
46,
467
]
],
[
[
372,
7,
2969
],
[
2969,
46,
467
]
],
[
[
372,
7,
4071
],
[
4071,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Clofarabine",
"{u} (Compound) downregulates {v} (Gene)",
"HDAC6"
],
[
"HDAC6",
"{u} (Gene) is upregulated by {... | Clofarabine (Compound) downregulates HDAC6 (Gene) and HDAC6 (Gene) is upregulated by Simvastatin (Compound)
Clofarabine (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Simvastatin (Compound)
Clofarabine (Compound) upregulates PNP (Gene) and PNP (Gene) is downregulated by Simvastatin (Compound)
... |
DB00595 | DB00688 | 1,545 | 955 | [
"DDInter1374",
"DDInter1251"
] | Oxytetracycline | Mycophenolate mofetil | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Moderate | 1 | [
[
[
1545,
24,
955
]
],
[
[
1545,
24,
1096
],
[
1096,
40,
955
]
],
[
[
1545,
24,
1114
],
[
1114,
62,
955
]
],
[
[
1545,
63,
1031
],
[
1031,... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycoph... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound)
Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc sulfate and Zinc sulfate may ... |
DB00719 | DB00776 | 1,219 | 1,335 | [
"DDInter149",
"DDInter1360"
] | Azatadine | Oxcarbazepine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
1219,
24,
1335
]
],
[
[
1219,
24,
1264
],
[
1264,
63,
1335
]
],
[
[
1219,
63,
1236
],
[
1236,
1,
1335
]
],
[
[
1219,
63,
902
],
[
902,... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamaz... |
DB01138 | DB06626 | 804 | 263 | [
"DDInter1726",
"DDInter147"
] | Sulfinpyrazone | Axitinib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Moderate | 1 | [
[
[
804,
24,
263
]
],
[
[
804,
24,
392
],
[
392,
24,
263
]
],
[
[
804,
24,
1593
],
[
1593,
63,
263
]
],
[
[
804,
62,
1101
],
[
1101,
... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Cr... |
DB00719 | DB00843 | 1,219 | 479 | [
"DDInter149",
"DDInter583"
] | Azatadine | Donepezil | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Moderate | 1 | [
[
[
1219,
24,
479
]
],
[
[
1219,
24,
843
],
[
843,
1,
479
]
],
[
[
1219,
6,
8374
],
[
8374,
45,
479
]
],
[
[
1219,
24,
1442
],
[
1442,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine and Tetrabenazine (Compound) resembles Donepezil (Compound)
Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Donepezil (Compound)
Azatadine may cause a moderate interaction that could exacerbate... |
DB00550 | DB09061 | 99 | 1,627 | [
"DDInter1541",
"DDInter284"
] | Propylthiouracil | Cannabidiol | A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534) | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
99,
24,
1627
]
],
[
[
99,
24,
384
],
[
384,
23,
1627
]
],
[
[
99,
24,
1613
],
[
1613,
63,
1627
]
],
[
[
99,
24,
267
],
[
267,
24... | [
[
[
"Propylthiouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Propylthiouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
... | Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Propylthiouracil may cause a moderate interaction that could exacerbate diseases when taken with Peginterfe... |
DB00889 | DB01041 | 1,133 | 770 | [
"DDInter840",
"DDInter1789"
] | Granisetron | Thalidomide | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1133,
24,
770
]
],
[
[
1133,
6,
7524
],
[
7524,
45,
770
]
],
[
[
1133,
21,
28789
],
[
28789,
60,
770
]
],
[
[
1133,
24,
609
],
[
609,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Granisetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound... | Granisetron (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Granisetron (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Granisetron may cause a moderate interaction that could exacerbate diseases when t... |
DB00439 | DB09570 | 289 | 1,480 | [
"DDInter341",
"DDInter1002"
] | Cerivastatin | Ixazomib | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
289,
24,
1480
]
],
[
[
289,
63,
268
],
[
268,
24,
1480
]
],
[
[
289,
24,
148
],
[
148,
63,
1480
]
],
[
[
289,
24,
310
],
[
310,
... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00951 | DB11703 | 1,072 | 405 | [
"DDInter986",
"DDInter9"
] | Isoniazid | Acalabrutinib | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
1072,
24,
405
]
],
[
[
1072,
63,
1324
],
[
1324,
24,
405
]
],
[
[
1072,
24,
951
],
[
951,
24,
405
]
],
[
[
1072,
24,
1297
],
[
1297,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[... | Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and ... |
DB00802 | DB01114 | 1,322 | 272 | [
"DDInter43",
"DDInter362"
] | Alfentanil | Chlorpheniramine | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
1322,
24,
272
]
],
[
[
1322,
24,
849
],
[
849,
63,
272
]
],
[
[
1322,
63,
128
],
[
128,
24,
272
]
],
[
[
1322,
6,
8374
],
[
8374,
... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniram... |
DB00872 | DB09143 | 1,080 | 313 | [
"DDInter438",
"DDInter1701"
] | Conivaptan | Sonidegib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
1080,
25,
313
]
],
[
[
1080,
24,
379
],
[
379,
23,
313
]
],
[
[
1080,
25,
478
],
[
478,
24,
313
]
],
[
[
1080,
25,
484
],
[
484,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazol... | Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Conivaptan may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a m... |
DB06791 | DB08907 | 1,446 | 1,344 | [
"DDInter1021",
"DDInter280"
] | Lanreotide | Canagliflozin | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1446,
24,
1344
]
],
[
[
1446,
63,
549
],
[
549,
1,
1344
]
],
[
[
1446,
63,
1523
],
[
1523,
24,
1344
]
],
[
[
1446,
24,
1296
],
[
1296,... | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may cause a moderate interaction tha... |
DB00395 | DB01041 | 210 | 770 | [
"DDInter301",
"DDInter1789"
] | Carisoprodol | Thalidomide | Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications. This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with b... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
210,
24,
770
]
],
[
[
210,
6,
10215
],
[
10215,
45,
770
]
],
[
[
210,
21,
28789
],
[
28789,
60,
770
]
],
[
[
210,
24,
849
],
[
849,
... | [
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Carisoprodol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Comp... | Carisoprodol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Thalidomide (Compound)
Carisoprodol (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Carisoprodol may cause a moderate interaction that could exacerbate diseases w... |
DB01177 | DB09083 | 77 | 880 | [
"DDInter904",
"DDInter996"
] | Idarubicin | Ivabradine | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
77,
25,
880
]
],
[
[
77,
63,
480
],
[
480,
24,
880
]
],
[
[
77,
24,
1478
],
[
1478,
24,
880
]
],
[
[
77,
24,
214
],
[
214,
63,
... | [
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaft... |
DB00238 | DB06616 | 188 | 594 | [
"DDInter1285",
"DDInter224"
] | Nevirapine | Bosutinib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
188,
24,
594
]
],
[
[
188,
24,
883
],
[
883,
1,
594
]
],
[
[
188,
6,
8374
],
[
8374,
45,
594
]
],
[
[
188,
21,
28709
],
[
28709,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Nevirapine (Compound) causes Decreased appetite (Side Effect) and Decr... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.